))
Dr. Jen Rogers on the Use of CB-CAPs to Assess Disease Activity in SLE
Manage episode 352279466 series 3428257
Content provided by Exagen Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Exagen Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
What is the Type 1 vs Type 2 Lupus Model? How does it shape the care and management of lupus patients? And what impact does it have on the future of drug development to address Type 2 symptoms?
Join Exagen and Dr. Jen Rogers, Director of the Duke Lupus Clinic as she breaks down the abstract, The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE, how the study came to be, and its clinical importance to both providers and patients.
3 episodes
Share
